Yuanpin Biotech

Yuanpin Biotech is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of next-generation cell therapies for oncology. The company primarily focuses on CAR-T and TCR-T modalities designed to target solid tumors, which remain a significant challenge for traditional immunotherapy. Its lead candidate, YP-001, is a GPC3-targeted CAR-T therapy currently undergoing clinical evaluation for the treatment of hepatocellular carcinoma. By utilizing proprietary engineering techniques, Yuanpin Biotech aims to improve the infiltration and survival of T cells within the tumor microenvironment to achieve superior clinical outcomes. The company's research and development efforts are supported by a team of experts in immunology and cell engineering. Yuanpin Biotech continues to expand its pipeline with candidates targeting various solid tumor antigens to address unmet medical needs in cancer treatment.